CL2022003289A1 - 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer - Google Patents

2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer

Info

Publication number
CL2022003289A1
CL2022003289A1 CL2022003289A CL2022003289A CL2022003289A1 CL 2022003289 A1 CL2022003289 A1 CL 2022003289A1 CL 2022003289 A CL2022003289 A CL 2022003289A CL 2022003289 A CL2022003289 A CL 2022003289A CL 2022003289 A1 CL2022003289 A1 CL 2022003289A1
Authority
CL
Chile
Prior art keywords
treatment
cyanothiophenes
annulled
cancer
amino
Prior art date
Application number
CL2022003289A
Other languages
English (en)
Inventor
Treu Matthias
Abbott Jason
Broeker Joachim
Cui Jianwen
W Fesik Stephen
Gollner Andreas
Hodges Tim
Karolyi-Oezguer Jale
Little Andrew
Mantoulidis Andreas
Phan Jason
Sarkar Dhruba
Sun Qi
Waterson Alex
Original Assignee
Boehringer Ingelheim Int
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Univ Vanderbilt filed Critical Boehringer Ingelheim Int
Publication of CL2022003289A1 publication Critical patent/CL2022003289A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Abstract

La presente invención comprende compuestos de la fórmula (I), en donde R1a, R1b, R2a, R2b, Z, R3 a R5, A, p, U, V, W, L y E tienen los significados dados en las reivindicaciones y la memoria descriptiva, su uso como inhibidores de proteínas mutantes de la familia Ras, composiciones farmacéuticas y preparaciones que contienen dichos compuestos y su uso como medicamentos/usos médicos, especialmente como agentes para el tratamiento y/o prevención de enfermedades oncológicas.
CL2022003289A 2020-06-02 2022-11-23 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer CL2022003289A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063033505P 2020-06-02 2020-06-02
EP20212067 2020-12-05

Publications (1)

Publication Number Publication Date
CL2022003289A1 true CL2022003289A1 (es) 2023-04-14

Family

ID=76269742

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003289A CL2022003289A1 (es) 2020-06-02 2022-11-23 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer

Country Status (18)

Country Link
US (2) US20230212164A1 (es)
EP (2) EP4157837A1 (es)
JP (2) JP2023527891A (es)
KR (1) KR20230019462A (es)
CN (2) CN116234806A (es)
AU (1) AU2021285032A1 (es)
BR (1) BR112022023462A2 (es)
CA (1) CA3183656A1 (es)
CL (1) CL2022003289A1 (es)
CO (1) CO2022017049A2 (es)
CR (1) CR20220614A (es)
DO (1) DOP2022000266A (es)
EC (1) ECSP22089077A (es)
IL (1) IL298633A (es)
MX (1) MX2022015260A (es)
PE (1) PE20240493A1 (es)
TW (1) TW202210474A (es)
WO (2) WO2021245051A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
KR20220071193A (ko) 2019-08-29 2022-05-31 미라티 테라퓨틱스, 인크. Kras g12d 억제제
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
MX2022007515A (es) 2019-12-20 2022-09-19 Mirati Therapeutics Inc Inhibidores de sos1.
US20230212164A1 (en) 2020-06-02 2023-07-06 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
US20220396589A1 (en) 2021-05-05 2022-12-15 Revolution Medicines, Inc. Ras inhibitors
AR125782A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
WO2023099612A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099592A1 (en) * 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099620A1 (en) * 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
WO2023099608A1 (en) * 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023117681A1 (en) * 2021-12-22 2023-06-29 Boehringer Ingelheim International Gmbh Heteroaromatic compounds for the treatment of cancer
WO2023126822A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and rasg12c inhibitor
WO2023154766A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2023244599A1 (en) * 2022-06-15 2023-12-21 Mirati Therapeutics, Inc. Pan-kras inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103396487A (zh) 2008-12-12 2013-11-20 贝林格尔.英格海姆国际有限公司 抗igf抗体
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
MY175950A (en) 2012-03-14 2020-07-16 Lupin Ltd Heterocyclyl compounds as mek inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
KR20160076519A (ko) * 2013-10-10 2016-06-30 아락세스 파마 엘엘씨 Kras g12c 억제제
EP3129380B1 (en) 2014-04-11 2018-11-28 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
US10576064B2 (en) 2014-07-03 2020-03-03 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
LT3183254T (lt) 2014-08-21 2019-08-26 Boehringer Ingelheim International Gmbh Naujieji spiro[3h-indol-3,2' -pirolidin]-2(1h)-ono junginiai ir dariniai, kaip mdm2-p53 inhibitoriai
UA123905C2 (uk) 2015-10-09 2021-06-23 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіро[3h-індол-3,2'-піролідин]-2(1h)-онові сполуки та похідні як інгібітори мdm2-p53
WO2017201161A1 (en) 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
US11325903B2 (en) * 2016-11-30 2022-05-10 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
JP7219218B2 (ja) 2016-12-22 2023-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
MX2019007643A (es) * 2016-12-22 2019-09-09 Amgen Inc Benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibirores de kras g12c para tratar el cancer de pulmon, pancreatico o colorrectal.
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
SI3710439T1 (sl) 2017-11-15 2023-06-30 Mirati Therapeutics, Inc., Zaviralci mutacije kras g12c
ES2944306T3 (es) 2017-12-21 2023-06-20 Boehringer Ingelheim Int Piridopirimidinonas sustituidas por bencilamino y derivados como inhibidores de SOS1
WO2019201848A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
EP3829580A1 (en) * 2018-08-01 2021-06-09 Araxes Pharma LLC Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
WO2020177629A1 (zh) 2019-03-01 2020-09-10 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
KR20210146287A (ko) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
BR112021023359A2 (pt) 2019-05-20 2022-02-01 1200 Pharma Llc Inibidores de g12c de kras e usos dos mesmos
MD3886991T2 (ro) 2019-12-11 2023-03-31 Lilly Co Eli Inhibitori KRAS G12C
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
CN113087700B (zh) 2020-01-08 2023-03-14 苏州亚盛药业有限公司 螺环四氢喹唑啉
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
CN113683616A (zh) 2020-05-18 2021-11-23 广州百霆医药科技有限公司 Kras g12c突变蛋白抑制剂
US20230212164A1 (en) 2020-06-02 2023-07-06 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
US20230227470A1 (en) 2021-12-01 2023-07-20 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099612A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099608A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099620A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes

Also Published As

Publication number Publication date
CR20220614A (es) 2023-05-08
DOP2022000266A (es) 2023-01-15
TW202210474A (zh) 2022-03-16
EP4157837A1 (en) 2023-04-05
AU2021285032A1 (en) 2022-12-08
JP2023528623A (ja) 2023-07-05
MX2022015260A (es) 2023-01-11
US20230212164A1 (en) 2023-07-06
CN116034106A (zh) 2023-04-28
WO2021245051A1 (en) 2021-12-09
JP2023527891A (ja) 2023-06-30
US20210380574A1 (en) 2021-12-09
WO2021245055A1 (en) 2021-12-09
IL298633A (en) 2023-01-01
BR112022023462A2 (pt) 2022-12-20
CA3183656A1 (en) 2021-12-09
ECSP22089077A (es) 2022-12-30
US11945812B2 (en) 2024-04-02
CN116234806A (zh) 2023-06-06
EP4157836A1 (en) 2023-04-05
CO2022017049A2 (es) 2023-02-06
KR20230019462A (ko) 2023-02-08
PE20240493A1 (es) 2024-03-15

Similar Documents

Publication Publication Date Title
CO2022017049A2 (es) 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer
CL2021000907A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020)
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
CL2023001738A1 (es) Inhibidores de prmt5
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CO2022015054A2 (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2
DOP2021000198A (es) Compuestos y su uso en el tratamiento del cáncer
ECSP23030959A (es) Compuestos y su uso en el tratamiento del cáncer
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
BR112023000212A2 (pt) Éter macrocíclico contendo derivados de indol como inibidores de mcl-1
BR112022008000A2 (pt) Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
ECSP18056196A (es) Derivados de indano
UY38133A (es) Nuevos inhibidores de cdk8/19
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
BR112022025631A2 (pt) Derivados de 4-(pirazol-5-il)-indol macrocíclico n-ligados como inibidores de mcl-1
BR112022024117A2 (pt) Derivados de 7-pirazol-5-il-indol macrocíclico como inibidores de mcl-1
AR126755A1 (es) Compuestos heterocíclicos y métodos de uso